Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

January 16, 2025

Study Completion Date

January 16, 2025

Conditions

HIV-1-infection

Interventions

DRUG

Vesatolimod

Administered orally

BIOLOGICAL

VRC07523LS

Administered intravenously

BIOLOGICAL

CAP256V2LS

Administered intravenously

Trial Locations (1)

FRESH Clinical Research Site: Females Rising through Education, Support and Health, Umlazi